Dr Lal Path Labs

Stocks to Watch, 27 October: Stocks like Kotak Mahindra Bank, Dr Reddy's Laboratories, SBI Life Insurance Company, Coforge, eClerx Services, Zydus Lifesciences, TGV Sraac, NCC,GPT Infraprojects, Epack Prefab Technologies, Vikran Engineering, RailTel Corporation of India, and Indian Oil Corporation will be in focus on October 27.

Dr Lal PathLabs: Exit of a company veteran stokes investor concerns

Om Manchanda, managing director of Lal PathLabs, is moving on to an advisory role after steering the company for close to two decades

Dr Lal PathLabs shares shed 6% amid profit booking after firm's Q2 net profit jumps 18%

Dr Lal PathLabs stock has been losing for the last two days and has fallen 7.34 percent in the period.

Dr Lal PathLabs Q1 profit up 29% at Rs 108 cr

The company had reported a profit after tax of Rs 84 crore in the April-June quarter of the last fiscal

Can Dr Lal PathLabs, Metropolis brave competition from new-age diagnostic rivals?

New-age players, in spite of cutting down on discounts, are seeing significantly higher revenue growth than incumbents.

Dr Lal PathLabs jumps 5% on double upgrade from Kotak Institutional Equities

Dr Lal PathLabs shares were trading at Rs 2,234.65, up nearly 5 percent from the previous close. The revised price target implies an upside of 8 percent from March 22 closing

Bonanza Portfolio's top stock picks amid ongoing market slump; check here

Bonanza Portfolio’s Omkar Kamtekar recommended investors buy into Dr Lal Path Labs, PCBL and Aavas Financers during the market downturn.

Why Dr Lal PathLabs’ fat profit margins are bringing no cheer

Business volumes lagged expectations as patient footfalls are largely unchanged in Q1 FY24 from year ago period

Short Call | Smallcaps on big strides, down swipe on SBI Cards, cracks in Shree Cements, block deals boom

Dealmaking by PE firms hit its lowest in four years in 2023 so far, as a lethal cocktail of high interest rates, recession fears, and weak outlook for corporate earnings are making investors jittery

Short Call | Smallcaps make big leaps, IEX in short squeeze, Tata Chem bulls charge, HDFC AMC in pressure

Fuelling the rally is the money flows coming through the mutual SIP route, a big chunk of which is now going into mid- and small-cap funds which have fared the best over the last couple of months

Is network expansion the booster dose diagnostic firms need?

Experts are bullish about the sector, and cite multiple tailwinds that would help drive growth, including increasing health awareness, potential industry consolidation, and more.

Dr Lal Path Labs Q2 PAT declines 25% to Rs 72.4 crore

The company had posted a profit after tax (PAT) of Rs 96.3 crore in the year-ago period.

Aarti Industries, Dr Lal Path Labs, HDFC AMC rise 2-4% on inclusion in F&O

Aarti Industries, Dr Lal Path Labs and HDFC Asset Management Company had a market capitalisation of Rs 21,253.99 crore, Rs 17,971.66 crore and Rs 60,410.85 crore respectively.